CN Patent

CN110446501A — 组织激肽释放酶1的剂型

Assigned to Diamedica Therapeutics Inc · Expires 2019-11-12 · 7y expired

What this patent protects

提供了一种或多种组织激肽释放酶‑1(KLK1)多肽的剂型，其具有约0.1μg/kg到约10.0μg/kg的总KLK1多肽剂量，包含皮下和静脉内剂型。还提供了例如用于治疗缺血性和出血性病状的相关装置及其使用方法。

USPTO Abstract

提供了一种或多种组织激肽释放酶‑1(KLK1)多肽的剂型，其具有约0.1μg/kg到约10.0μg/kg的总KLK1多肽剂量，包含皮下和静脉内剂型。还提供了例如用于治疗缺血性和出血性病状的相关装置及其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN110446501A
Jurisdiction
CN
Classification
—
Expires
2019-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Diamedica Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.